Written answers

Tuesday, 2 February 2016

Department of Health

Long-Term Illness Scheme

Photo of Billy KelleherBilly Kelleher (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

420. To ask the Minister for Health the status of the provision of Fampyra and the restrictions that have been placed on covering the cost of the medication by the Health Service Executive; and if he will make a statement on the matter. [4592/16]

Photo of Kathleen LynchKathleen Lynch (Cork North Central, Labour)
Link to this: Individually | In context | Oireachtas source

Fampridine (brand name Fampyra®) has been reimbursed under the Long Term Illness Scheme on a conditional, responder-only basis since 1 October 2015.

The HSE has provided all Neurology Centres with details of the protocol which must be satisfied to enable a patient to qualify for reimbursement.

Reimbursement will be extended where a demonstration of clinical response (based on objective criteria agreed with clinical experts) is recorded and where that clinical response is shown to persist, based on objective measurement at six-monthly intervals. The HSE extends reimbursement in all cases where the criteria meet the requirements of reimbursement protocol.

Comments

No comments

Log in or join to post a public comment.